Similar articles for PMID: 33789932

Year	Number of Results
2016	1
2017	4
2018	4
2019	12
2020	17
2021	27
2022	22
2023	39
2024	7

1

Assessing Response to [¹⁷⁷Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria.

Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Michalski K, et al. J Nucl Med. 2021 Mar 31;62(12):1741-6. doi: 10.2967/jnumed.120.260836. Online ahead of print. J Nucl Med. 2021. PMID: 33789932 Free PMC article.

2

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.

Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Gafita A, et al. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. Epub 2022 Jun 29. Eur J Nucl Med Mol Imaging. 2022. PMID: 35767071

3

Prognostic Value of Tumor Volume Assessment on PSMA PET After ¹⁷⁷Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.

Kind F, Eder AC, Jilg CA, Hartrampf PE, Meyer PT, Ruf J, Michalski K. Kind F, et al. J Nucl Med. 2023 Apr;64(4):605-610. doi: 10.2967/jnumed.122.264489. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302658 Free article.

4

Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with ¹⁷⁷Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.

Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Murthy V, et al. J Nucl Med. 2023 Nov;64(11):1737-1743. doi: 10.2967/jnumed.122.265155. Epub 2023 Sep 7. J Nucl Med. 2023. PMID: 37678927

5

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2^nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With ¹⁷⁷Lu-PSMA.

Prasad V, Huang K, Prasad S, Makowski MR, Czech N, Brenner W. Prasad V, et al. Front Oncol. 2021 Mar 17;11:578093. doi: 10.3389/fonc.2021.578093. eCollection 2021. Front Oncol. 2021. PMID: 33816225 Free PMC article.

6

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112. doi: 10.1007/s00259-020-04828-5. Epub 2020 May 6. Eur J Nucl Med Mol Imaging. 2021. PMID: 32378019

7

Response assessment using ⁶⁸Ga-PSMA ligand PET in patients undergoing ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.

8

Prognostic implications of dual tracer PET/CT: PSMA ligand and [¹⁸F]FDG PET/CT in patients undergoing [¹⁷⁷Lu]PSMA radioligand therapy.

Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, Hartrampf PE. Michalski K, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2024-2030. doi: 10.1007/s00259-020-05160-8. Epub 2020 Dec 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33336265 Free PMC article.

9

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [¹⁷⁷Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome.

Hartrampf PE, Lapa C, Serfling SE, Buck AK, Seitz AK, Meyer PT, Ruf J, Michalski K. Hartrampf PE, et al. Cancers (Basel). 2021 Aug 25;13(17):4270. doi: 10.3390/cancers13174270. Cancers (Basel). 2021. PMID: 34503080 Free PMC article.

10

Early molecular imaging response assessment based on determination of total viable tumor burden in [⁶⁸Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy.

Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. Rosar F, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725725 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year